Isoray, Inc.
New York Stock Exchange ArcaCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Lori A. Holmes-Woods
- Full Time Employees
- 66
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 350 Hills Street Richland WA United States of America 99354
- IPO Date
- May 31, 2002
- CIK
- 0000728387
- Website
- isoray.com
- Similar Companies
- Business
- Isoray, Inc. is a medical technology company specializing in the development, manufacturing, and sale of isotope-based medical products and devices focused on cancer treatment through seed brachytherapy. The company's core product portfolio includes Cesium-131 brachytherapy seeds for low dose rate (LDR) radiation therapy, radiation treatment planning software, and proprietary delivery systems for the implantation of radioactive seeds primarily targeting cancers such as prostate, brain, lung, head and neck, and gynecological tumors. Isoray operates primarily through its subsidiary IsoRay Medical, Inc., with a focus on markets in the United States, Europe, and Asia. The company was founded in 1999 and is headquartered in Richland, Washington. In recent major developments, Isoray completed a significant merger with Viewpoint Molecular Targeting, Inc. in early 2023, expanding its capabilities in targeted alpha-particle radiopharmaceutical therapies and advancing a pipeline of proprietary targeting peptides for tumor diagnosis and treatment. This strategic merger reoriented the company to focus on precision, targeted radiation therapies for cancer, incorporating advances in radiopharmaceuticals and imaging technologies to deliver personalized medical doses directly to tumor sites. Additionally, in late 2023, Isoray announced the divestiture of its radioactive Cesium-131 brachytherapy seed assets and related infrastructure to GT Medical Technologies, a transaction expected to close in the first quarter of 2024, which will streamline operations and strengthen partnerships within the oncology community. Isoray's product offerings include implantable Cesium-131 seeds used in various brachytherapy applications such as prostate cancer and recurrent brain tumors, supported by proprietary delivery systems like the Build-Blu delivery system for in-surgery custom strand building. The company has heavily invested in research and development to enhance treatment protocols and expand its product range. Isoray also maintains collaborations with leading healthcare institutions including Johns Hopkins University, Cleveland Clinic, and Mayo Clinic, supporting clinical research and innovation in cancer treatment. The company operates within the medical device and oncology segments, targeting hospitals, clinics, and specialized cancer treatment centers. With a mission focused on advancing cancer treatment modalities, Isoray emphasizes innovation in radiopharmaceuticals and therapeutic isotopes to improve patient outcomes. Recent structural changes, including the merger and asset divestiture, reflect a strategic repositioning to concentrate on alpha-particle therapies and complementary molecular targeting technologies while supporting its legacy seed brachytherapy business through partnerships. Isoray, Inc. continues to evolve within the medical technology landscape with a foundation in isotope-based cancer therapeutics, headquartered in Richland, Washington, and with a strategic focus on expanding precision oncology treatments globally. Its recent merger and asset transitions mark significant steps toward broadening its technological and therapeutic footprint in the oncology market.
Is Northrop Grumman Expanding Its Presence in the ISR Market?
AIRO's RQ-35 Heidrun ISR Drone Added To U.S. Blue UAS List
BlackSky to Field Mission-Critical Gen-3 AI Solutions that Enhance Real-time, Space-based Tactical ISR Operations
Teledyne FLIR OEM Launches Prism Ground ISR Software for Tactical Perception and Military Target Classification
Nexus Uranium Congratulates enCore Energy on Landmark Federal Regulatory Approvals Advancing ISR Uranium in South Dakota
EagleNXT Secures Order of eBee VISION ISR and eBee TAC Systems from Asia Pacific Customer
AIRO Debuts RQ-70 Long-Range ISR Drone Platform at Eurosatory 2026, Advancing Multi-Product Growth Strategy
Ur-Energy Celebrates 100th Shipment of Yellowcake from Lost Creek ISR Uranium Mine, Wyoming
Eviden and Hexadrone combine their expertise to equip modular drones with SIGINT capabilities
Haivision Introduces Play ISR Premium for Video Analysis, Collaboration, and Situational Awareness
Uranium Energy Corp Reports Results for the Third Quarter of Fiscal 2026
Teledyne FLIR OEM Launches Boson SX8, the First NDAA-Compliant 8 µm SXGA LWIR Thermal Camera Module
enCore Energy Announces the Successful Completion of Construction at the Upper Spring Creek ISR Uranium Project
Zorronet Brings Autonomous C5ISR to Hardened Sites Without Public Cloud Dependence
American Uranium Reports Strong Early Infill Drilling Results at its 9.45Mlb Lo Herma ISR Uranium Project in Wyoming's Powder River Basin Ahead of Q3 Resource Upgrade
Haivision Delivers AI-Enabled ISR Ecosystem with the Launch of Kobra, an Ultra-Portable Video Operations Platform for the Tactical Edge
XTEND Secures Seven-Figure Defense ISR Order in Asia-Pacific
Denison Reports Financial and Operational Results for Q1 2026, Highlighted by Commencement of Site Preparation and Early Works for the Phoenix ISR Uranium Mine, and the Results of its Shareholder Meeting
American Uranium Commences Drilling at its Lo Herma ISR Uranium Project in Wyoming's Powder River Basin
EagleNXT Receives Additional Order for eBee VISION ISR Systems from U.S. Army's 7th Army Training Command